Our CEO & Co-founder, , speaks with Labiotech on their Beyond Biotech podcast about our origins, clinical progress, and the potential of our approach in developing treatments for autoimmune diseases.
Listen now 🎙ï¸
â€
â€
01:19-04:12: About 91±¬ÁϳÉÈËƬ Therapeutics
04:12-04:51: The origins of the name
04:51-06:52: The three ‘signals’ of the mechanics of immunological responses
06:52-08:31: Treatments associated with each signal
08:31-10:09: Why is step 1 important, and why has it not been investigated for treatments?
10:09-11:28: What areas of disease is this applicable to?
11:28-12:19: How do you inhibit ERAP?
12:19-14:01: 91±¬ÁϳÉÈËƬ Therapeutics’ candidates
14:01-15:11: How is this an advance on current treatments?
15:11-16:05: What is success for patients?
16:05-17:20: How does the stage of disease affect treatment?
17:20-18:09: Are other companies looking into antigen modulation?
18:09-19:47: Has this led to investment opportunities?
19:47-21:15: Next steps
21:15-21:55: Do you anticipate more interest in this space?
21:55-23:21: Attending events
â€
